TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Community Based Interventions to Reduce Neonatal Mortality in Bangladesh
Brief Summary: This project delivers, promotes and facilitates services related to pregnancy, delivery and newborn care.


Options:
A: Neonatal mortality rate
B: Neonatal death (28 days)
C: Change in target behaviour: zinc use (six weeks post-intervention); Change in target behaviour: correct ORS preparation (six weeks post-intervention); Change in target behaviour: Exclusive breastfeeding (six weeks post-intervention); Change in target behaviour: Handwashing with soap (six weeks post-intervention)
D: Use of iron-folic acid supplements (IFA tablets used during 9 months of last pregnancy among recently delivered women with children <6 months of age by June 2016); Use of calcium supplements (Calcium tablets used during 9 months of last pregnancy among recently delivered women with children <6 months of age by June 2016); Dietary diversity during pregnancy (Pregnant women in second and third trimester of pregnancy (4-9 months) by June- August 2016); Dietary micronutrient intakes (Pregnant women in second and third trimester of pregnancy (4-9 months) by June- August 2016); Coverage of maternal nutrition intervention (1 year)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Community Based Interventions to Reduce Neonatal Mortality in Bangladesh
Brief Summary: This project delivers, promotes and facilitates services related to pregnancy, delivery and newborn care.


Options:
A: Study the effect of a standard two-encounter postnatal lactation counseling protocol on the initiation and maintenance of exclusive breastfeeding in mothers
B: Effectiveness of a nutrition advice programme in exclusive breastfeeding. (1 year); Effectiveness of a nutrition advice programme in dietary intake (1 year); Effectiveness of a nutrition advice programme in dietary intake (4 years); Effectiveness of a nutrition advice programme in dietary intake (8 years); Effectiveness of a nutrition advice programme in dietary intake (12 years)
C: Neonatal mortality rate
D: Exclusive Breastfeeding Rates in Burkina Faso (at 3 months of age); Infant Morbidity, 2 Week Diarrhoea Prevalence (at 3 months of age); Exclusive Breastfeeding Rates in Uganda (at 3 months of age); Exclusive Breastfeeding Rates in South Africa (at 3 months of age)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Community Based Interventions to Reduce Neonatal Mortality in Bangladesh
Brief Summary: This project delivers, promotes and facilitates services related to pregnancy, delivery and newborn care.


Options:
A: Neonatal mortality from post enrolment to 28 days (From post enrolment to 28 days); Early infant mortality from post enrolment to 6 months of age (From post enrolment to 6 months)
B: Neonatal mortality rate
C: Neurodevelopment as measured by the Protocol for Child Monitoring - Infant and Toddler version assessment (12 months of age)
D: perinatal mortality (Jan 1999-Dec 2003)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Community Based Interventions to Reduce Neonatal Mortality in Bangladesh
Brief Summary: This project delivers, promotes and facilitates services related to pregnancy, delivery and newborn care.


Options:
A: Sexually transmitted disease (Measured at 2nd and 3rd trimesters and Months 6 and 12 postpartum); Rapid repeat pregnancy (Measured at Month 12 postpartum); Sexual risk behavior (Measured at 2nd and 3rd trimesters and Months 6 and 12 postpartum); Perinatal outcomes (e.g., birth weight, gestational age) (Measured at Months 6 and 12 postpartum)
B: perinatal mortality (Jan 1999-Dec 2003)
C: increase the proportion of institutional deliveries in intervention vs. control clusters (Up to 15 months)
D: Neonatal mortality rate

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Community Based Interventions to Reduce Neonatal Mortality in Bangladesh
Brief Summary: This project delivers, promotes and facilitates services related to pregnancy, delivery and newborn care.


Options:
A: Neonatal mortality (7 days)
B: Health workers will visit households at three month intervals for 18 months and survey the status of the babies.
C: Baby's health status (6 days after birth; 6 months after birth; 12 months after birth)
D: Neonatal mortality rate

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Community Based Interventions to Reduce Neonatal Mortality in Bangladesh
Brief Summary: This project delivers, promotes and facilitates services related to pregnancy, delivery and newborn care.


Options:
A: Post day 1 Neonatal mortality (birth to 28 days of age) in the communities receiving the intervention(cohort of infants born to women identified through pregnancy surveillance) (Over 30 Months); Neonatal mortality (from birth to 28 days of age) in the cohort identified through pregnancy surveillance (Over 30 Months); Post day 1 neonatal mortality (1 to 28 days of age) in the population of newborns who are more likely to have greater impact from the intervention i.e. those born at home and available in the study area within 7 days of birth (30 months); Neonatal mortality (from birth to 28 days of age) in the population more likely to benefit from the intervention (30 months); Infant mortality (birth to 365 days) in the communities receiving the intervention. (30 months)
B: Neonatal mortality rate
C: mortality (day 28)
D: All cause Neonatal Mortality (2 years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Community Based Interventions to Reduce Neonatal Mortality in Bangladesh
Brief Summary: This project delivers, promotes and facilitates services related to pregnancy, delivery and newborn care.


Options:
A: Exclusive breastfeeding (6 months postpartum)
B: Proportion of women who exclusively breastfeed to 6 months (The outcome will be measured when the infant is 6-7 months old.)
C: Neonatal mortality rate
D: Newborn survival (to 28 days) (July 2010 to June 2013)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
Brief Summary: The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three months postpartum, can reduce the risk of maternal mortality, fetal loss, or infant mortality.


Options:
A: Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate (20 weeks through discharge following delivery); Severe Hypertension (20 weeks through discharge following delivery); Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme Levels (20 weeks through discharge following delivery); Severe or Mild Pregnancy-associated Hypertension With Thrombocytopenia (20 weeks through discharge following delivery); Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine Level (20 weeks through discharge following delivery); Severe or Mild Pregnancy-associated Hypertension With an Eclamptic Seizure (20 weeks through discharge following delivery); Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32 Weeks of Gestation Owing to Hypertension-related Disorders (20 weeks through discharge following delivery); Severe or Mild Pregnancy-associated Hypertension With a Fetus That Was Small for Gestational Age (Below the 3rd Percentile) Adjusted for Sex and Race or Ethnic Group (20 weeks through discharge following delivery); Severe or Mild Pregnancy-associated Hypertension With a Fetal Death After 20 Weeks of Gestation or Neonatal Death (20 weeks through discharge or prior to discharge following delivery admission)
B: Fetal loss, low birth weight and pre-term birth. (Delivery)
C: Weight, length and Rohrer index at birth, and gestational duration in single pregnancies. (At birth); Mortality, morbidity and growth during the first year of life (Monthly during infancy)
D: All-cause, Pregnancy-related Mortality (Deaths during pregnancy through 12 weeks postpartum)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
Brief Summary: The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three months postpartum, can reduce the risk of maternal mortality, fetal loss, or infant mortality.


Options:
A: Weight, length and Rohrer index at birth, and gestational duration in single pregnancies. (At birth); Mortality, morbidity and growth during the first year of life (Monthly during infancy)
B: cell-free viral load and/or cell-associated proviral load in breast milk (Delivery, 3 months, and 6 months after delivery); concentration of vitamins A, B12, and E in breast milk (Delivery, 3 months, and 6 months post-delivery); subclinical mastitis (Delivery, 3 months, and 6 months after delivery)
C: Pregnancy-related mortality and all cause mortality (Continuous)
D: All-cause, Pregnancy-related Mortality (Deaths during pregnancy through 12 weeks postpartum)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
Brief Summary: The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three months postpartum, can reduce the risk of maternal mortality, fetal loss, or infant mortality.


Options:
A: N/A
B: Proportion of enrolled patients who attend for their assigned screening test (Immediate)
C: Change in stage of adoption of health behaviors and referral for additional screening and follow up for high risk participants at 6 month post evaluation
D: All-cause, Pregnancy-related Mortality (Deaths during pregnancy through 12 weeks postpartum)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
Brief Summary: The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three months postpartum, can reduce the risk of maternal mortality, fetal loss, or infant mortality.


Options:
A: All-cause, Pregnancy-related Mortality (Deaths during pregnancy through 12 weeks postpartum)
B: Pregnancy-related mortality and all cause mortality (Continuous)
C: N/A
D: Breast milk immune regulators (Four months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
Brief Summary: The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three months postpartum, can reduce the risk of maternal mortality, fetal loss, or infant mortality.


Options:
A: All-cause, Pregnancy-related Mortality (Deaths during pregnancy through 12 weeks postpartum)
B: Thymus size measured by ultrasound (through 15 wk of age); peripheral blood naive T-helper lymphocyte concentration (through 15 wk of age); T-cell receptor excision circle (TREC) level in peripheral blood mononuclear cells (PBMC) (through 15 wk of age); T-cell response to BCG (Bacillus Calmette-Guérin; to protect against tuberculosis) and oral polio virus (OPV) immunization (through 15 wk of age); Antibody response to oral polio virus (OPV) immunization (through 15 wk of age); T-cell and antibody response to tetanus toxoid (TT) and hepatitis B virus (HBV) vaccinations given at 6, 10 and 14 wk of age (through 15 wk of age); bacterial translocation to blood (through 15 wk of age)
C: Mortality; Morbidity; All outcomes are investigated for interactions between vitamin A, sex, and last vaccine received
D: N/A

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Evaluation Research of the Nutrition Interventions in the INHP II Areas of CARE India
Brief Summary: This study is designed to evaluate the effectiveness of CARE India's Integrated Nutrition and Health Program (INHP II) to reduce malnutrition among children 0-23 months of age.


Options:
A: Prevalence of underweight among children 0-23 months; Prevalence of stunting among children 0-23 months; Prevalence of wasting among children 0-23 months; Prevalence of anemia among children 12-23 months
B: Change in Length-for-age Z scores (LAZ) at 3, 6, 12, 18 and 24 months age of children in intervention vs. comparison arms, compared to the baseline LAZ at 7 days of birth. (1, 3, 6, 9, 12, 15, 18, 21 and 24 months of child's age)
C: Excessive weight gain (0-6 months)
D: Effectiveness of a nutrition advice programme in exclusive breastfeeding. (1 year); Effectiveness of a nutrition advice programme in dietary intake (1 year); Effectiveness of a nutrition advice programme in dietary intake (4 years); Effectiveness of a nutrition advice programme in dietary intake (8 years); Effectiveness of a nutrition advice programme in dietary intake (12 years)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study
Brief Summary: This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative 3-arms of 140 patients (i.e. 420 total patients).

Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months


Options:
A: Evaluation of the prevalence of symptomatic or asymptomatic deep venous thrombosis in cancer patients with implantable device for central venous access with or without prophylaxis : (Day90); Low molecular weight Heparin (LMWH) 2500 U anti-XA/day or Warfarine 1 mg/day during the first line of chemotherapy (Day90)
B: Complete Response Rate (Up to 8 years post-registration); Event-free Survival (Up to 8 years post-registration); Disease-free Survival (Up to 8 years post-registration); Overall Survival (Up to 8 years post-registration); Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event at Least Possibly Related to Treatment (Toxicity) (Up to 10 years post-registration)
C: Percentage of Participants With Time to First Occurrence of Primary Efficacy Endpoint (Composite and Components) (Up to Day 180); Percentage of Participants With Time to the First Occurrence of Major Bleeding Events as Defined by International Society of Thrombosis and Haemostasis (ISTH) (From first dose of study drug to 2 days after the last dose of the study drug (up to 32 weeks))
D: Cumulative incidence of symptomatic venous and arterial thromboembolism, in patients with metastatic or locally advanced solid tumors undergoing chemotherapy (Events occurring during the four months of treatment plus 10 days)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study
Brief Summary: This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative 3-arms of 140 patients (i.e. 420 total patients).

Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months


Options:
A: Documentation of Serious Adverse Events (SAE) with the use of a 30% ethanol / 4% sodium citrate catheter locking solution. (6 months)
B: Evaluation of the prevalence of symptomatic or asymptomatic deep venous thrombosis in cancer patients with implantable device for central venous access with or without prophylaxis : (Day90); Low molecular weight Heparin (LMWH) 2500 U anti-XA/day or Warfarine 1 mg/day during the first line of chemotherapy (Day90)
C: time between episodes of central line infection in one patient
D: To show that AAT-023 (Zuragen) solution is superior to Heparin in preventing CRBSI when used as a catheter lock solution in CVCD's between hemodialysis treatments. (6 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study
Brief Summary: This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative 3-arms of 140 patients (i.e. 420 total patients).

Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months


Options:
A: Documentation of Serious Adverse Events (SAE) with the use of a 30% ethanol / 4% sodium citrate catheter locking solution. (6 months)
B: To show that AAT-023 (Zuragen) solution is superior to Heparin in preventing CRBSI when used as a catheter lock solution in CVCD's between hemodialysis treatments. (6 months)
C: time between episodes of central line infection in one patient
D: Evaluation of the prevalence of symptomatic or asymptomatic deep venous thrombosis in cancer patients with implantable device for central venous access with or without prophylaxis : (Day90); Low molecular weight Heparin (LMWH) 2500 U anti-XA/day or Warfarine 1 mg/day during the first line of chemotherapy (Day90)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study
Brief Summary: This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative 3-arms of 140 patients (i.e. 420 total patients).

Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months


Options:
A: Percentage of Patients With Venous Thromboembolisms (12 weeks); Percentage of Patients Who Experienced Clinically Significant Bleeding Events. (13 weeks)
B: Evaluation of the prevalence of symptomatic or asymptomatic deep venous thrombosis in cancer patients with implantable device for central venous access with or without prophylaxis : (Day90); Low molecular weight Heparin (LMWH) 2500 U anti-XA/day or Warfarine 1 mg/day during the first line of chemotherapy (Day90)
C: Composite of Recurrent VTE or VTE Death at 36 Months (36 months); Composite of Recurrent VTE or VTE Death at 18 Months (18 months)
D: symptomatic objectively confirmed VTE, asymptomatic ultrasonography-confirmed DVT or VTE-related death (30 days)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Autologous Stem Cell Transplantation in Acute Myocardial Infarction
Brief Summary: Objectives

Intracoronary transplantation of different cell populations have been used in acute myocardial infarction (AMI) with promising results. The primary objective of the ASTAMI study is to test whether intracoronary transplantation of autologous mononuclear bone marrow cells (mBMC) improve left ventricular ejection fraction (LVEF) after anterior wall AMI.

Design

The ASTAMI study is a randomized, controlled, prospective study. One hundred patients with acute anterior wall ST-elevation myocardial infarction (STEMI) treated with acute PCI are randomized in a 1:1 way to either intracoronary transplantation of autologous mBMC 5-8 days after PCI or to control. Left ventricular function, exercise capacity, biochemical status, functional class, quality of life and complications are validated at baseline and during a 12-month follow up.


Options:
A: Global Left Ventricular Ejection Fraction change (6 months)
B: whether intracoronary mBMC transplantation improve LVEF after AMI assessed by ECG-gated SPECT.
C: Change in global left ventricular ejection fraction (LVEF) at 4 months relative to baseline measured by quantitative MRI (4 months)
D: The primary objective is to demonstrate the safety of autologous cardiosphere-derived stem cells administered by intra-coronary infusion in patients with ischemic left ventricular dysfunction and a recent myocardial infarction. (6 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: The Effectiveness of Shortwave Diathermy in Knee Osteoarthritis: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether shortwave diathermy is effective in reducing knee pain and increasing function of the patients with knee osteoarthritis.


Options:
A: Change From Baseline in Pain Perception Measured on Visual Analog Score (VAS) at Week 4 (baseline and 4 weeks); Changes From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at Week 4 (baseline and 4 weeks)
B: Pain evaluation (1 year follow up)
C: The Visual Analog Scale (VAS) (Change from Baseline in Visual Analog Scale at Immediate post-intervention); The Visual Analog Scale (VAS) (Change from Baseline in Visual Analog Scale at 2 days); Western Ontario and McMaster Universities (WOMAC) Index (Change from Baseline in WOMAC at 2 days); Self-Leeds Assessment of Neuropathic Symptoms and signs (S-LANSS) Scale (At Baseline); Pressure Pain Threshold (PPT) (Change from Baseline in PPT at Immediate post-intervention); Pressure Pain Threshold (PPT) (Change from Baseline in PPT at 2 days); Thermal Perception and Pain Thresholds (Change from Baseline in Thermal Perception and Pain Thresholds at Immediate post-intervention); Thermal Perception and Pain Thresholds (Change from Baseline in Thermal Perception and Pain Thresholds at 2 days); Hand-Held Dynamometer (Change from Baseline in Hand-Held Dynamometer at Immediate post-intervention); Hand-Held Dynamometer (Change from Baseline in Hand-Held Dynamometer at 2 days); Standard Goniometer (Change from Baseline in Standard Goniometer at Immediate post-intervention); Standard Goniometer (Change from Baseline in Standard Goniometer at 2 days); Three-meter Timed "Up and Go" (Change from Baseline in Three-meter Timed "Up and Go" at Immediate post-intervention); Three-meter Timed "Up and Go" (Change from Baseline in Three-meter Timed "Up and Go" at 2 days)
D: The Change in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index (3 weeks)

Answer: D